SOLIQS is a leader in drug delivery with marketed products and a proven track record in enhancing the bioavailability of poorly soluble compounds using its platform technologies Meltrex, Xellex, NanoMorph, SoliScreen and now smartCrystal.

SOLIQS will take all efforts to provide customized solutions and give you consultative support to your situation.

SOLIQS Technology Platform Offers:

• Novel oral dosage forms for compounds with solubility challenges or that require specifically designed release profiles
• Improved clinical profiles (safety, efficacy) and patient compliance
• Reducing pill burden to patients
• Minimized food effect and/or gastric irritation
• Reduced intra- and interpatient variability
• Significant reduction in dose while maintaining therapeutic efficacy
• Increased R&D productivity and throughput
• Solvent free process with GRAS approved exipients
• Extended patent life

SOLIQS provides Solid Solutions for Insoluble Substances®.

Symposium on Pharmaceutical Melt Extrusion

From Concept to Commercialization

9-10 October 2008, in Ludwigshafen, Germany

During the symposium, the Grand Opening of the new SOLIQS development facilities were celebrated. Dignitaries and representatives from politics, academia, industry, and the media participated. ... download the latest press release

The presentations of the speakters are online NOW. Open Symposium page